RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study

Sponsor
Cambridge University Hospitals NHS Foundation Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT04233268
Collaborator
(none)
250
1
56.8
4.4

Study Details

Study Description

Brief Summary

Lower Respiratory Tract infections are a common cause of admission to the intensive care unit. Children routinely receive antibiotics until the tests confirm whether the infection is bacterial or viral. The exclusion of bacterial infection may take 48 hours or longer for culture tests on biological samples to be completed. In many cases, the results may be inconclusive or negative if the patient has already received antibiotics prior to the sample being taken.

A rapid assay to detect the most likely cause of infection could improve the speed with which antibiotic therapy is rationalised or curtailed.

This study aims to assess whether a new genetic testing kit which can identify the presence of bacteria and viruses within hours rather than days is a feasible tool in improving antibiotic prescribing and rationalisation of therapy in critically ill children with suspected lower respiratory tract infection.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Rapid Pathogen Detection

Study Design

Study Type:
Observational
Anticipated Enrollment :
250 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study
Actual Study Start Date :
Jun 6, 2020
Anticipated Primary Completion Date :
Feb 28, 2023
Anticipated Study Completion Date :
Feb 28, 2025

Arms and Interventions

Arm Intervention/Treatment
Critically ill children

Children with severe infection requiring mechanical ventilation

Diagnostic Test: Rapid Pathogen Detection
Rapid assays for pathogen detection on bronchoalveolar lavage fluid

Non critically ill cohort

Children with severe infection admitted to hospital but not requiring mechanical ventilation

Profiling of the respiratory microbiome

Mechanically ventilated children of any cause admitted to PICU

Diagnostic Test: Rapid Pathogen Detection
Rapid assays for pathogen detection on bronchoalveolar lavage fluid

Outcome Measures

Primary Outcome Measures

  1. Performance of the novel pathogen detection assay [3 years]

    Performance of novel pathogen detection assays compared to standard microbiology, in regard to sensitivity, specificity and likelihood ratios

Secondary Outcome Measures

  1. Time to results [3 years]

    Time to reportable test results

  2. Negative cultures [3 years]

    Where routine culture is negative, what proportion of tests have a positive detection using the novel assay?

  3. Antibiotic therapy [3 years]

    Duration of therapy and number of antibiotic classes during paediatric intensive care unit admission

Other Outcome Measures

  1. Prevalence of COVID19 in children admitted to PICU [2 years]

    Number of critically ill children requiring mechanical ventilation with COVID19 compared to those without

  2. Prevalence of SARS-CoV-2 antigen in faecal samples following acute admission with COVID-19 related illness [2 years]

    Faecal excretion of SARS-CoV-2

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Months to 16 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged >37 weeks corrected gestation and ≤16 years old

  2. Receiving mechanical ventilation

  3. Commencing or already receiving antibiotic treatment for lower respiratory tract infection

Exclusion Criteria:
  1. Survival not expected/active medical treatment expected to be withdrawn/palliative care only

Contacts and Locations

Locations

Site City State Country Postal Code
1 Addenbrooke's Hospital Cambridge Cambs United Kingdom CB2 9NS

Sponsors and Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

Investigators

  • Principal Investigator: Nazima Pathan, FRCPCH PhD, Cambridge University Hospitals NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Nazima Pathan, University Lecturer in Paediatric Intensive Care, Cambridge University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT04233268
Other Study ID Numbers:
  • 277039
First Posted:
Jan 18, 2020
Last Update Posted:
Oct 20, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 20, 2021